Golfer’s elbow — medically known as medial epicondylitis — affects far more people than golfers. It is a tendon condition that develops on the inner side of the elbow, where the forearm muscles attach to the bony bump at the elbow’s medial epicondyle. Repetitive gripping, wrist flexion, and forearm rotation gradually damage the tendon over time. The result is persistent pain, weakness in grip, and in many cases, a long and frustrating recovery.

For most patients, the standard treatment path looks familiar: rest, physiotherapy, anti-inflammatory medication, and corticosteroid injections. These approaches can reduce pain short-term, but they do not address the underlying tissue damage. When conservative treatment fails — which happens in a meaningful number of chronic cases — patients are often left choosing between extended rest or surgery. Stem cell therapy is increasingly being studied as an alternative path between those two options.

Why Tendons Are Difficult to Heal

Tendons have a limited blood supply compared to muscle or bone. When a tendon is damaged, the body’s natural repair process tends to produce disorganised scar tissue rather than restoring the original collagen architecture. This is why tendinopathy can become a chronic condition — the tendon heals, but not correctly. The structural weakness remains, and the pain returns with activity.

This biology is central to understanding why conventional injections often provide only temporary relief. Corticosteroids reduce inflammation, but they do not rebuild tissue. Over time, repeated injections can actually weaken tendon structure further.

How Mesenchymal Stem Cells Approach the Problem Differently

Mesenchymal stem cells — particularly those derived from umbilical cord tissue (UC-MSCs) — work through a different set of mechanisms. Research shows that MSCs promote tendon repair by reducing inflammation, supporting new blood vessel formation, and encouraging the production and reorganisation of collagen — including a shift from disorganised type III collagen toward structurally stronger type I collagen.

UC-MSCs have received particular attention as a cell source for tendon applications. Studies have demonstrated that umbilical cord-derived MSCs can be directed toward tenogenic (tendon-forming) differentiation, producing collagen type I and key structural markers associated with healthy tendon tissue. Because these cells are sourced from donated umbilical cord tissue rather than the patient, they are available as a ready-to-use therapy without requiring a separate harvesting procedure from the patient.

Beyond their differentiation potential, MSCs also have paracrine effects — meaning they secrete growth factors and signalling molecules that stimulate local tissue repair, even in areas where the cells themselves may not permanently engraft. This dual action, both direct and signalling-based, makes them a more biologically active option than conventional injections.

What the Clinical Evidence Shows

Research specifically on stem cell therapy for elbow tendinopathy is still developing, but early findings are encouraging. A reported case involving a professional golfer with confirmed intrasubstance tendon tear showed progressive pain reduction and functional improvement following MSC treatment, with repeat imaging at 18 months demonstrating regeneration of tendon-like tissue — and sustained structural improvement at 30 months of follow-up.

A systematic review and meta-analysis of prospective clinical studies on MSC therapy for tendon disorders — which included elbow tendinopathy and golfer’s elbow among the conditions studied — examined outcomes across PubMed-MEDLINE, EMBASE, and the Cochrane Library to evaluate efficacy and safety.

Who Tends to Be a Candidate for This Approach

Stem cell therapyfor golfer’s elbow is typically considered for patients who have not responded to a structured course of conservative treatment — usually defined as physiotherapy, activity modification, and possibly one or two corticosteroid injections over several months. Patients with confirmed tendon degeneration on imaging (ultrasound or MRI) are generally better candidates than those with purely inflammatory presentations in early stages.

A physician consultation and imaging review are essential first steps. Not every case of medial elbow pain is medial epicondylitis, and not every confirmed case will benefit from regenerative intervention. Case selection matters significantly in this area of medicine.

Realistic Expectations

Stem cell therapy is not a fast fix. Tendon tissue remodels slowly by nature — meaningful improvement in both pain and structural integrity typically develops over weeks to months following treatment. Patients are generally advised to maintain a structured rehabilitation programme alongside any regenerative therapy, as the biological repair process still requires appropriate mechanical loading to produce well-organised tissue.

The goal of treatment is not simply pain suppression, but tissue restoration — reducing the likelihood of recurrence and supporting a return to full function over time.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

• Ni M, Zhang C, Tang Y. Mechanisms of mesenchymal stem cell-mediated tendon repair and regeneration. Stem Cells International. 2023;2023:8851745. https://doi.org/10.1155/2023/8851745
• Pas HIMFL, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. British Journal of Sports Medicine. 2017;51(13):996–1002. https://doi.org/10.1136/bjsports-2016-096794
• Zhu J, Li J, Dou Y, et al. Mesenchymal stem cells use in the treatment of tendon disorders: A systematic review and meta-analysis of prospective clinical studies. Annals of Rehabilitation Medicine. 2021;45(4):267–282. https://e-arm.org/journal/view.php?number=4227
• Citeroni MR, Mauro A, Coppola L, et al. Pulsed electromagnetic fields improve tenogenic commitment of umbilical cord-derived mesenchymal stem cells. Cells. 2018;7(9):pmc6091420. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091420/